LEESAR, INC – FDA Untitled Letter, Oct 29, 2021

Record Details

This UNTITLED LETTER record concerns LEESAR, INC, with an inspection on October 29, 2021, issued by the Office of Pharmaceutical Quality, covering drugs.

Company: LEESAR, INC
Inspection date: October 29, 2021
Product type: Drugs
Office: Office of Pharmaceutical Quality
People: José R. Lopez (Program Expert)
James R. Boswell
Mark W. Rivero (Compliance Officer)

View Company Profile

ID · 8be237a3-e954-4817-8ae4-f0842ff3fda4

Violation Codes8

21 U.S.C. 353b21 CFR 21021 CFR 211.19221 CFR 201.11521 U.S.C. 351(a)(2)(B)21 U.S.C. 360eee-121 U.S.C. 351(a)(2)(A)21 U.S.C. 355(a)

Full citation text and observation details available on the Dashboard.

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore LEESAR, INC

UNTITLED LETTER

LEESAR, INCOctober 29, 2021

LEESAR, INC – FDA Untitled Letter, Oct 29, 2021

Record Details

This UNTITLED LETTER record concerns LEESAR, INC, with an inspection on October 29, 2021, issued by the Office of Pharmaceutical Quality, covering drugs.

Company: LEESAR, INC
Inspection date: October 29, 2021
Product type: Drugs
Office: Office of Pharmaceutical Quality
People: José R. Lopez (Program Expert)
James R. Boswell
Mark W. Rivero (Compliance Officer)

View Company Profile

ID · 8be237a3-e954-4817-8ae4-f0842ff3fda4

Violation Codes8

21 U.S.C. 353b21 CFR 21021 CFR 211.19221 CFR 201.11521 U.S.C. 351(a)(2)(B)21 U.S.C. 360eee-121 U.S.C. 351(a)(2)(A)21 U.S.C. 355(a)

Full citation text and observation details available on the Dashboard.

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore LEESAR, INC